ArticleThe Prostate2026
Exploring the Gut-Prostate Axis: Microbial Signatures Linked to Prostate Volume and Bladder Function.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The gut-prostate axis in benign prostatic diseases: Mechanistic pathways and therapeutic implications.iScience · 2026Review
- Molecular Mechanisms of Gut Microbiota-Immune System Crosstalk: From Mucosal Architecture to Adaptive Immunity Programming.International journal of molecular sciences · 2026Review
- Exploring the Gut-Prostate Axis: Microbial Signatures Linked to Prostate Volume and Bladder Function.The Prostate · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBenign prostatic hyperplasia (BPH) is a common urologic condition in aging men, often linked to systemic inflammation and metabolic dysfunction. Emerging evidence suggests that the gut microbiome may contribute to prostate health and disease. Here we aim to explore potential associations between gut microbiota composition and clinical parameters, such as prostate volume (PV) and residual bladder volume (RBV).
methodsThis cross-sectional study analyzed stool samples from 28 patients undergoing transurethral surgery. Gut microbiota composition was analyzed using 16S rRNA gene sequencing. Patients were stratified into groups based on PV ( ≤ 40 mL vs. > 40 mL) and RBV ( ≤ 100 mL vs. > 100 mL). α-diversity (Chao1 and Shannon indices) and β-diversity (Jaccard distance) were calculated. Linear discriminant analysis effect size (LEfSe) was used to identify differentially abundant taxa between groups.
resultsNo significant differences in gut microbial α- or β-diversity were observed between groups stratified by PV or RBV. Nevertheless, several specific bacterial taxa showed significant variation between groups. Methanobrevibacter smithii was markedly less abundant in patients with PV > 40 mL (p < 0.01). Similarly, patients with high RBV ( ≥ 100 mL) exhibited distinct gut microbial profiles compared to those with lower RBV, characterized by a reduced abundance of Collinsella and an increased abundance of Gastranaerophilales (both p < 0.01).
conclusionOur findings suggest that while overall gut microbial diversity may remain stable, specific taxa are associated with prostate and bladder phenotypes, supporting the concept of a gut-prostate axis. Future research should focus on longitudinal studies to investigate how gut (and urinary) microbiota evolve alongside BPH and/or LUTS over time, with the goal of determining whether microbial signatures could serve as early indicators for symptomatic BPH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.